A Next Generation of Pneumococcal Disease Protection

Released On
December 30, 2021

Expires On
December 30, 2022

Media Type

Completion Time
90 minutes

Infectious Disease, Pharmacy, Primary Care

Adult Vaccines, CDC, Pediatrics

Scroll to the Bottom of this Information to Begin this Course

Sponsored by The Academy for Continued Healthcare Learning (ACHL).


This activity is supported through an Independent Medical Education grant from Merck & Co., Inc.

Credit Available

  • Physicians — maximum of 1.5 AMA PRA Category 1 Credits
  • Pharmacists — 1.50 Contact Hours
  • Nurses — 1.5 contact hours.

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity is intended for infectious disease specialists, primary care physicians, advanced practice providers, pharmacists, nurses and other clinicians who manage adult patients for whom pneumococcal vaccination is recommended.

Program Overview

In this modular video-based activity, multidisciplinary faculty provide their perspectives on the changing epidemiology of pneumococcal disease and the protection afforded by a next generation of conjugate vaccines. Hear expert insights on considerations for next generation pneumococcal vaccine use, patient access, and strategies for engaging patients. Two case studies are discussed to drive home practical strategies to use in day-to-day practice.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Explain the rationale behind the development of next generation pneumococcal conjugate vaccines
  • Identify highest-risk groups who should receive PCV15 versus PCV20
  • Formulate strategies to engage patients in shared clinical decision-making per CDC recommendations




Michael Hogue, PharmD, FAPhA, FNAP

Dean and Professor
Loma Linda University - School of Pharmacy
Professor of Preventive Medicine, School of Medicine
Director, Center for Interprofessional Education & Practice
Loma Linda University
Loma Linda, CA


Donald B. Middleton, MD

Professor of Family Medicine
University of Pittsburgh School of Medicine
UPMC St. Margaret
Pittsburgh, PA


Stephen Pelton, MD

Professor of Pediatrics
Boston University School of Medicine
Senior Attending Physician in Pediatric Infectious Diseases
Boston Medical Center
Boston, MA



Module 1: Overview of Next-Generation Pneumococcal Vaccines
Module 2: Considerations for Ensuring Optimal Pneumococcal Vaccine Uptake
Module 3: Case-based Discussion Regarding Next-Generation Vaccines


Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.


This activity has been approved for 1.50 contact hours.

ACPE Universal Activity Number: 0396-0000-21-055-H06-P
Activity Type(s): Application
Release Date: December 30, 2021
Expiration Date: December 30, 2022

Continuing Nursing Education Statement

Provider approved by the California Board of Registered Nursing, Provider Number 17273 for 1.50 contact hours.

Disclosures of Conflicts of Interest

ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

The following faculty financial relationships have been provided:

Michael Hogue, PharmD, FAPhA, FNAP has no financial relationships to disclose.

Donald B. Middleton, MD
  • Advisor or Review Panel member: Pfizer Inc.
  • Consultant (occasional): Pfizer Inc.
  • Speaker Bureau: Pfizer Inc.
Stephen Pelton, MD
  • Advisor or Review Panel member: Glaxo Smith Kline, Merck, Pfizer Inc, Sanofi Pasteur, Seqirus.
  • Consultant (occasional): Glaxo Smith Kline, Seqirus, Merck, Pfizer Inc.
  • Grant/Research Support recipient: Merck, Pfizer Inc.

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None.

Instructions for Participation and Credit

This activity will take up to 90 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

For questions, contact Laurie Novoryta at Lnovoryta@achlcme.org.

CPE credit will be submitted to CPE Monitor® on the first day of each month.

Course Viewing Requirements

  • Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
  • Compatible with Windows PC and MAC (256 MB of RAM or higher)
  • Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
  • Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
  • Adobe Reader to print certificate. Click here to download Adobe Reader for free.
  • Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
  • Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker

Disclosure of Unlabeled Use

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.


The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, as well as the ACPE Accreditation Standards for Continuing Pharmacy Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Contact Information

For CME questions please contact: Lnovoryta@achlcme.org